In light of a recent American Heart Association report stating that U.S. mitral valve regurgitation prevalence was 1.7 percent in 2014, a significant opportunity exists for development of an effective transcatheter mitral valve replacement (TMVR) device as an alternative treatment to surgery for inoperable patients. This assessment was given by an analyst with research and consulting firm GlobalData.

Daiichi Sankyo and the Heart Rhythm Society announced results from a global survey, which polled cardiologists from around the world and revealed that a majority (58 percent) agree there is no such thing as a "typical" non-valvular atrial fibrillation (NVAF) patient.

The National Forum for Heart Disease & Stroke Prevention announced the launch of the Stronger Hearts Helpline, a 24/7 free call-center resource for people with heart failure and their families. The pilot program is an addition to the existing 2-1-1 information and referral hotline in San Bernardino County, California – a region where nearly 20 percent of Medicare recipients are being treated for heart failure – and long-term plans are to expand the service nationwide.

Americans are ready and willing to leverage health apps and wearable devices to improve their personal health, according to the findings released from the fifth annual Makovsky/Kelton "Pulse of Online Health" Survey.

Medtronic announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for the company’s IN.PACT Admiral drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system (OPPS). The decision removes a potential barrier to patient access to this new medical device, which represents an improvement to the standard of care for peripheral arterial disease in the upper leg.

C. R. Bard Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for the Lutonix drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system. This approval follows a unanimous favorable recommendation from the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Advisory Panel.

Pie Medical Imaging BV announced that it received 510(k) clearance from the U.S. Food and Drug Administration for its CAAS A-Valve product including the quantitative Regurgitation Analysis (qRA) workflow. The qRA workflow is the first 510(k) cleared image analysis technology to determine aortic regurgitation based on X-ray angiography.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now